Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
131
resultados
Última actualización
09/03/2025 [07:42:00]
Resumen de: US2025074902A1
Provided are a fused bicyclic heteroaryl amide compound as a protein aggregation inhibitor, as well as the use of such compound in the treatment or prevention of neurodegenerative diseases characterized by protein aggregation, such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, and cancer.
Resumen de: US2025073341A1
The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
Resumen de: WO2025048759A1
The present invention pertains to benzimidazole derivatives of formula (I) and their inhibitory activity against mPGES-1. It also encompasses pharmaceutical compositions that include these benzimidazole derivatives and their application in treating mPGES-1-mediated diseases. The purpose of this invention is to create novel compounds that inhibit inducible mPGES-1, an enzyme responsible for catalyzing the final step in the biosynthesis of PGE2 from AA. These compounds are intended for the treatment of various inflammatory conditions, including but not limited to Parkinson's disease, autoimmune diseases, allergic disorders, rhinitis, coronary heart disease, ulcers, osteoarthritis, rheumatoid arthritis, systemic sclerosis, periodontitis, colon cancer, inflammatory bowel disease, cutaneous sclerosis, neuropathic pain, inflammation, pain, fever, migraine, chronic pain, acute pain, headache, asthma, pulmonary fibrosis, fibromyalgia, dysmenorrhea, atherosclerosis, gout, arthritis, rheumatic fever, multiple sclerosis, Hodgkin's disease.
Resumen de: WO2025049979A1
Disclosed herein are peptides or peptoids including from 8 to 20 amino acids, including a plurality of hydrophobic amino acids and a plurality of charged amino acids, wherein spacing of the plurality of hydrophobic amino acids and the plurality of charged amino acids aligns with the spacing of hydrophobic amino acids and oppositely charged amino acids in an ApoE protein or polypeptide. Also disclosed are pharmaceutical compositions that include a peptide or peptoid as disclosed, as well as various methods of using the peptides or peptoids, and such pharmaceutical compositions. These methods include blocking Aβ/ApoE interaction, inhibiting Aβ protein oligomerization, and inhibiting amyloid plaque and/or tau aggregate formation, as well as the treatment of Alzheimer's Disease and other tauopathies.
Resumen de: WO2025049807A1
Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other secondary Parkinsonian disorders. Disclosed are DA neuronal cells that have been modified in vitro with a genetic insertion of GDNF. The GDNF coding sequence is inserted under the transcriptional control of a promotor such that secreted proteins are made and taken up by the endogenous cells after the administered engineered cells have matured to a Neuronal Mature Cell Type to promote survival of endogenous neurons. Also disclosed are DA neuronal cells that have been modified with a genetic insertion of GBA in vitro and are hemizygous null for SNCA. The GBA coding sequence is inserted under the transcriptional control of a ubiquitous promotor and the secreted proteins are made and taken up by the graft and endogenous cells immediately upon transplantation to promote long-term graft integrity.
Resumen de: WO2025048409A1
The compound represented by chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, according to one aspect, can be used as a prophylactic or therapeutic agent for degenerative diseases such as age-related macular degeneration (AMD) in which lack of HTRA1 activity is a factor in worsening the disease, cerebral amyloid angiopathy, hereditary stroke (CADASIL), and Alzheimer's disease (AD), and can be used as an adjuvant for efficiently and accurately screening an HTRA activity modulator without a change in temperature or addition of a substrate.
Resumen de: WO2025048007A1
The present invention relates to use of a novel compound for preventing, alleviating or treating Alzheimer's disease, and the novel compound exhibits an inhibitory effect on tau protein aggregation. In addition, it was identified that presenilin 1 was reduced by treatment using the novel compound. Therefore, the novel compound can be effectively used in the development of a therapeutic agent for Alzheimer's disease.
Resumen de: US2025074951A1
The present invention relates to the discovery of compositions and methods for altering Amyloid Precursor Protein (APP) processing. Alerting APP processing is aids the treatment of neuropathological disorders such as those associated with HIV infection and Alzheimer's disease (AD). The invention includes fusion protein constructs that include an effector protein and an HSV US9 protein or functionally active fragment thereof that reduce the amount of amyloid □-protein produced in a cell.
Resumen de: WO2025045033A1
Provided are a gene therapy vector for treating Parkinson's disease and a use thereof. Specifically, provided is an adeno-associated virus (AAV) vector for treating Parkinson's disease, which can simultaneously express functional tyrosine hydroxylase (TH), GTP-cyclohydrolase 1 (GCH1) and aromatic amino acid decarboxylase (AADC) to promote dopamine synthesis. Also provided are an AAV virus particle containing the AAV vector, a composition containing the AAV vector or the AAV virus particle, and uses of the AAV vector, the AAV virus particle and the composition in the preparation of drugs for preventing or treating Parkinson's disease.
Resumen de: WO2025044931A1
Provided is an antibody that binds to β-amyloid (Aβ), or an antigen-binding fragment thereof. Further provided are a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a cell comprising the antibody or the antigen-binding fragment or nucleic acid thereof, a pharmaceutical composition, a kit, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug used for treating or preventing a disease caused by abnormal accumulation or deposition of Aβ in subjects.
Resumen de: AU2023326620A1
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of "wearing-off", the treatment comprising administering more than N doses of levodopa per day to provide a total daily dose of X mg of levodopa and administering a single daily dose of Y mg of opicapone, wherein X is from 100 to 1000, N is from 2 to 10 and Y is from 25 to 50.
Resumen de: AU2023312980A1
The present disclosure provides methods, compositions and kits for prophylactic treating or preventing a degenerative disease related to amyloid. The compositions and kits comprise Sigma-1 receptor agonist, an allosteric sigma agonist, and/or a dual agonist of Sigma-1 and M1. The compositions and kits elicit effects of delaying the onset, deterring the progress, and/or diminish the likelihood of the degenerative disease, such as deterring the memory loss and/or cognition decline in Alzheimer's disease.
Resumen de: US2025074973A1
The present disclosure relates generally to methods of treating Huntington's disease in a subject in need thereof. The method comprises determining that the subject has an elevated level of C4a or an elevated C4a/C4 ratio; and administering to the subject an inhibitor of the classical complement pathway.
Resumen de: WO2023209010A1
The present invention generally relates to the treatment of Parkinson's disease (PD) in humans. More particularly, it relates to nicotinamide riboside (NR) for use in a method for treatment of Parkinson's disease in a human subject characterized by a particular dosage regimen; pharmaceutical compositions; and dosage forms, which can be for use in or as treatment of Parkinson's disease.
Resumen de: EP4516792A1
The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION,or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.
Resumen de: EP4516782A1
The present disclosure relates to novel crystalline forms of Blarcamesine hydrocholoride (hereinafter referred to as "compound I"), a method for preparing same, a pharmaceutical composition comprising the crystalline forms, and use of the crystalline forms in preparing a Sigma-1 receptor agonist and a medicament for treating Rett syndrome, Alzheimer's disease, and Parkinson's disease dementia.
Resumen de: US2025066364A1
The invention provides substituted pyrazolo1,5-apyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo1,5-apyrimidine compounds described herein include 5,7-dimethyl-N-phenylpyrazolo1,5-apyrimidine-3-carboxamide compounds and variants thereof.
Resumen de: US2025066434A1
The present disclosure provides compositions and methods for modulating transcription of mutant C9orf72 gene alleles in patients in need thereof, including patients having a C9orf72-related disease such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).
Resumen de: US2025066433A1
The present disclosure provides compositions and methods for modulating transcription of mutant C9orf72 gene alleles in patients in need thereof, including patients having a C9orf72-related disease such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).
Resumen de: US2025066330A1
The invention provides a compound of formula (1), or a pharmaceutically acceptable salt, ester or carbamate thereof, or a salt of such an ester or carbamate,wherein either:R1 is OH, and R2 is H; orR1 is H, and R2 is OH.The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, progressive supranuclear palsy and corticobasal degeneration, or for the prevention or treatment of a disease or disorder such as Alzheimer's disease, progressive supranuclear palsy and corticobasal degeneration.
Resumen de: US2025066336A1
The invention provides novel ligands of Kappa (κ) opioid receptors, such as can be used to modulate a Kappa opioid receptor. Methods of synthesis and methods of use are also provided. Compounds of the invention can be used therapeutically in the treatment of dissociative disorders or pain, or to provide neuroprotection, or to induce diuresis, or to modulate the immune system, or for treatment of one or more of an affective disorders comprising depression or stress/anxiety; an addictive disorder; alcoholism, epilepsy; a cognition deficiency; schizophrenia; Alzheimer's disease; or pain.
Resumen de: US2025066774A1
Disclosed herein are engineered latent guide RNAs targeting LRRK2 and compositions comprising the same for treatment of diseases or conditions (e.g. Parkinson's Disease) in a subject. Also disclosed herein are methods of treating diseases or conditions (e.g. Parkinson's Disease) in a subject by administering engineered latent guide RNAs or pharmaceutical compositions described herein.
Resumen de: US2025064776A1
A method for treating or preventing amyotrophic lateral sclerosis (ALS) or other motor neuron disease in a subject, the method comprising administering to the subject a PKC activating compound (e.g., a bryostatin, such as bryostatin-1, or a bryolog) in a therapeutically effective amount to treat or prevent the motor neuron disease by activating PKC in the subject. The ALS may be, for example, classical ALS, primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and progressive bulbar palsy (PBP). The PKC activating compound may be administered at an initial loading dose of about 15, 24, or 48 micrograms weekly in the first one week or consecutive two or three weeks, followed by doses of about 12, 20, or 40 micrograms alternately every two or three weeks for at least 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24, or 30 total weeks.
Resumen de: US2025064970A1
L-N-isobutyryl cysteine (L-NIBC)-bound gold cluster Au18(L-NIBC)14, its use for treating multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma, and the use of it for manufacturing a medicament for treatment of multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma. Composition and methods for treating multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma.
Nº publicación: US2025064879A1 27/02/2025
Solicitante:
KOREA INST OF ORIENTAL MEDICINE [KR]
DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECH [KR]
KOREA INSTITUTE OF ORIENTAL MEDICINE,
DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
Resumen de: US2025064879A1
The present invention relates to a composition for treating, improving, or preventing Alzheimer's disease caused by ApoE4 gene mutation, the composition including Banha-Sasim-Tang as an active ingredient.The composition including Banha-Sasim-Tang as an active ingredient of the present invention and a treatment method exhibit excellent effects of reducing amyloid beta proteins and inhibiting deposition thereof, which are specific to Alzheimer's disease caused by ApoE4 gene mutation, thereby having high applicability as a specific composition for preventing, improving, or treating Alzheimer's disease caused by ApoE4 gene mutation.
BOPI
Sede Electrónica
